Research record
Pembrolizumab
Pembrolizumab is a PD-1 immune checkpoint inhibitor. It belongs in immunotherapy discussions rather than MEK/targeted-therapy discussions.
What this is
Pembrolizumab is a PD-1 immune checkpoint inhibitor. It belongs in immunotherapy discussions rather than MEK/targeted-therapy discussions.
Why it may come up
- adjuvant
- cannot be removed by surgery
- has spread
- context-dependent
What not to assume
- No direct comparison claim against nivolumab without a source.
At a glance
Pembrolizumab
- Type
- Immunotherapy
- Mutation result
- any
- Where
- US, Korea, Japan, China, EU
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- NCI melanoma treatment sources include immune checkpoint inhibitor treatment categories.
- KCIC identifies pembrolizumab in Korean checkpoint-inhibitor education.
What is unclear
- Korean, Japanese, Chinese, and EU reimbursement/label details still need country-specific source mapping.
Questions to ask
- Why pembrolizumab rather than another checkpoint option?
- What prior therapies affect this choice?
- What should we ask before moving to the next line if it stops working?